ARGENX SE (ARGX.BR) Stock Fundamental Analysis
EBR:ARGX - NL0010832176 - Common Stock
639.8 EUR
+8.4 (+1.33%)
ARGX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. ARGX has an excellent financial health rating, but there are some minor concerns on its profitability. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, ARGX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year ARGX was profitable.
ARGX had a positive operating cash flow in the past year.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ARGX's Return On Assets of 17.84% is amongst the best of the industry. ARGX outperforms 93.24% of its industry peers.
With an excellent Return On Equity value of 21.00%, ARGX belongs to the best of the industry, outperforming 86.49% of the companies in the same industry.
ARGX has a Return On Invested Capital of 5.71%. This is amongst the best in the industry. ARGX outperforms 82.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.71% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARGX's Profit Margin of 41.97% is amongst the best of the industry. ARGX outperforms 94.59% of its industry peers.
ARGX has a Operating Margin of 15.30%. This is amongst the best in the industry. ARGX outperforms 83.78% of its industry peers.
ARGX's Gross Margin of 89.40% is amongst the best of the industry. ARGX outperforms 86.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ARGX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARGX has more shares outstanding
Compared to 1 year ago, ARGX has a worse debt to assets ratio.
2.2 Solvency
ARGX has an Altman-Z score of 26.43. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
ARGX has a Altman-Z score of 26.43. This is amongst the best in the industry. ARGX outperforms 95.95% of its industry peers.
The Debt to FCF ratio of ARGX is 0.14, which is an excellent value as it means it would take ARGX, only 0.14 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.14, ARGX belongs to the top of the industry, outperforming 98.65% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.01, ARGX belongs to the best of the industry, outperforming 83.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 26.43 |
ROIC/WACC0.77
WACC7.39%
2.3 Liquidity
A Current Ratio of 5.60 indicates that ARGX has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.60, ARGX is doing good in the industry, outperforming 79.73% of the companies in the same industry.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a better Quick ratio (5.27) than 79.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 345.45%, which is quite impressive.
ARGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.80%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
Revenue 1Y (TTM)56.8%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%97.62%
3.2 Future
ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 98.67% yearly.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 31.90% on average per year.
EPS Next Y754%
EPS Next 2Y269.03%
EPS Next 3Y162.09%
EPS Next 5Y98.67%
Revenue Next Year81.09%
Revenue Next 2Y53.73%
Revenue Next 3Y42.43%
Revenue Next 5Y31.9%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 86.23, the valuation of ARGX can be described as expensive.
ARGX's Price/Earnings ratio is a bit cheaper when compared to the industry. ARGX is cheaper than 77.03% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.06, ARGX is valued quite expensively.
ARGX is valuated quite expensively with a Price/Forward Earnings ratio of 31.63.
Based on the Price/Forward Earnings ratio, ARGX is valued a bit cheaper than 77.03% of the companies in the same industry.
ARGX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 86.23 | ||
| Fwd PE | 31.63 |
4.2 Price Multiples
ARGX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ARGX is cheaper than 71.62% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 78.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 147.72 | ||
| EV/EBITDA | 80.36 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 162.09% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y269.03%
EPS Next 3Y162.09%
5. Dividend
5.1 Amount
No dividends for ARGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:ARGX (9/5/2025, 7:00:00 PM)
639.8
+8.4 (+1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners39.98%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap39.16B
Analysts84.8
Price Target708.84 (10.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14%
Revenue beat(16)13
Avg Revenue beat(16)17.53%
PT rev (1m)3.4%
PT rev (3m)1.41%
EPS NQ rev (1m)23.69%
EPS NQ rev (3m)63.09%
EPS NY rev (1m)26.21%
EPS NY rev (3m)26.21%
Revenue NQ rev (1m)10.81%
Revenue NQ rev (3m)20.1%
Revenue NY rev (1m)7.8%
Revenue NY rev (3m)9.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 86.23 | ||
| Fwd PE | 31.63 | ||
| P/S | 14.95 | ||
| P/FCF | 147.72 | ||
| P/OCF | 112.95 | ||
| P/B | 7.48 | ||
| P/tB | 7.76 | ||
| EV/EBITDA | 80.36 |
EPS(TTM)7.42
EY1.16%
EPS(NY)20.23
Fwd EY3.16%
FCF(TTM)4.33
FCFY0.68%
OCF(TTM)5.66
OCFY0.89%
SpS42.8
BVpS85.52
TBVpS82.45
PEG (NY)0.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.71% | ||
| ROICexc | 15.87% | ||
| ROICexgc | 17.62% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 26.43 |
F-Score5
WACC7.39%
ROIC/WACC0.77
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
EPS Next Y754%
EPS Next 2Y269.03%
EPS Next 3Y162.09%
EPS Next 5Y98.67%
Revenue 1Y (TTM)56.8%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%97.62%
Revenue Next Year81.09%
Revenue Next 2Y53.73%
Revenue Next 3Y42.43%
Revenue Next 5Y31.9%
EBIT growth 1Y207%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1034.03%
EBIT Next 3Y192.38%
EBIT Next 5Y113.51%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.79%
OCF growth 3YN/A
OCF growth 5YN/A